Category Blog

Blog, PARP Inhibitors in BRCA mutations

Molecular Mechanisms of Synthetic Lethality: A Clinical Review of PARP Inhibition in BRCA-Mutated Malignancies

Diagram of synthetic lethality mechanism: PARP inhibition in BRCA-mutant cancer cells leading to apoptosis vs. survival in healthy cells.

Medically Reviewed by: Dr. Salma Elreedy, Clinical Oncologist, Sphinx Cure Oncology Center. Fact-Checked by: Generic Oncology Editorial Team. Synthetic lethality is a genetic phenomenon where the simultaneous loss of function in two separate genes results in cell death, while the…

Salma Abdel, Evidence-Based Medical Researcher
March 28, 2026

Supportive & Palliative Care, Blog

Supportive and Palliative Oncology: Clinical Protocols for Quality of Life

chemotherapy induced nausea and vomitting prevention diagram in Supportive and Palliative Oncology

Protocol Overview Historically, the discipline of clinical oncology maintained a singular, aggressive focus on tumor eradication. The primary metric of success was the reduction of tumor burden, often at the severe expense of the patient’s physical and psychological tolerance. Today,…

Salma Abdel, Evidence-Based Medical Researcher
March 26, 2026

Blog, Generic oncolgoy medicines

Evolving Production Standards and Accessibility in Generic Oncology Therapeutics

We have moved beyond the era where cancer care was defined strictly by high-cost, exclusive branded drugs accessible only to a small percentage of the global population. Today, the focus has shifted toward the democratization of treatment through scientific advancement…

Salma Abdel, Evidence-Based Medical Researcher
March 25, 2026

Generic oncolgoy medicines, Blog

Strategies for Managing and Reducing Cancer Medication Costs: A 2026 Guide

The financial burden of cancer medication costs is often described by the medical community as “Financial Toxicity.” This is not just a term for high bills; it is a clinical reality that affects how well a patient recovers. When the…

Salma Abdel, Evidence-Based Medical Researcher
March 23, 2026

Blog

The Clinical Integration of Generic Oncology Medicines

The Science of Molecular Identity and Bioequivalence of Generic Oncology Medicines

Article Overview The news of a cancer diagnosis is a life-changing event that brings immediate emotional and practical challenges. Beyond the medical complexities of the disease, the cost of treatment often becomes a primary concern for patients and their families.…

Salma Abdel, Evidence-Based Medical Researcher
March 20, 2026

Blog, Generic oncolgoy medicines

How Generic Oncology Medicines Reduce the Financial Burden of Cancer Treatment

How Generic oncology medicines reduce the financial toxicity of cancer care

The diagnosis of cancer brings a sudden and immense weight to any family. While the primary goal is health and recovery, the conversation quickly turns to the high cost of treatment. In the medical world, the financial strain of caring…

Salma Abdel, Evidence-Based Medical Researcher
March 19, 2026

Blog, Acute Myeloid Leukemia Treatment, Precision Oncology

Clinical Guide to the FLT3 Mutation in Acute Myeloid Leukemia (AML)

Table of Content A primary diagnosis of Acute Myeloid Leukemia (AML) introduces patients and their families to a highly complex landscape of hematology, molecular biology, and genomic profiling. Modern precision oncology no longer relies solely on identifying the morphological type…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Non-small Cell Lung Cancer Targeted Therapy, Blog

Clinical Guide to the BRAF Mutation and Targeted Therapy

Understanding your pathology report and genetic testing is the first step in precision oncology. If your tumor tissue has tested positive for a BRAF mutation, your medical team has identified the specific genetic driver responsible for your cancer’s growth. This…

Salma Abdel, Evidence-Based Medical Researcher
March 14, 2026

Blog, Non-small Cell Lung Cancer Targeted Therapy

ROS1 Gene Fusions in NSCLC: Targeted Therapies and Clinical Management

Receiving a cancer diagnosis immediately thrusts you into a complex world of medical terminology, cellular biology, and genetic testing. Today, oncology relies heavily on understanding the unique genetic blueprint of a tumor. Instead of categorizing cancer solely by where it…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Blog

KRAS G12C Mutation in Advanced NSCLC: Targeted Therapies and Clinical Management

KRAS G12C Mutation involvement in non-small cell lung cancer. The Diagram shows the historical data of this mutation.

A cancer diagnosis often introduces a completely new vocabulary. You might hear your oncology team discuss genes, mutations, and targeted therapies. In modern oncology, treating cancer requires understanding the specific genetic blueprint of the tumor. One of the most significant…

Salma Abdel, Evidence-Based Medical Researcher
March 12, 2026

Trending now